Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams

Combination of Assertio’s Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth across All Products

Transaction Expected to Be Accretive to Assertio’s Adjusted EPS and Operating Cash Flow in 2024

Spectrum Stockholders Will Receive significant benefits from Assertio Holding, Inc’s acquisition of Spectrum. The transaction will bring together complementary commercial growth platforms aimed at accelerating the profitability of ROLVEDON™ (eflapegrastim-xnst) Injection and diversifying revenue streams. Assertio’s omni-channel digital sales capabilities, combined with ROLVEDON’s in-person commercial team, are expected to enhance market access and drive growth across all products.

The acquisition is projected to have a positive impact on Assertio’s adjusted earnings per share (EPS) and operating cash flow by the year 2024. Spectrum stockholders will benefit from the synergies created by the merger, leading to a more robust and profitable combined entity.

How will this affect me?

As a consumer, this acquisition may result in improved access to innovative pharmaceutical products, including ROLVEDON™ (eflapegrastim-xnst) Injection. The enhanced commercial capabilities of the combined entity may lead to better distribution channels, potentially making it easier for individuals to access necessary medications.

How will this affect the world?

The acquisition of Spectrum by Assertio Holdings, Inc. has the potential to impact the pharmaceutical industry by creating a more competitive and diversified market. The collaboration of different commercial growth platforms could lead to the development of new business strategies and innovative approaches to reaching consumers worldwide. Overall, this merger may contribute to the advancement of healthcare and pharmaceutical research on a global scale.

Conclusion

The acquisition of Spectrum by Assertio Holdings, Inc. represents a significant step towards accelerating commercial growth and diversifying revenue streams in the pharmaceutical industry. With a focus on enhancing market access and driving profitability, this transaction is expected to bring about positive outcomes for both companies and stakeholders involved. As the combined entity continues to evolve and innovate, the impact of this acquisition is likely to extend beyond the companies involved, shaping the future of healthcare and pharmaceuticals worldwide.